Northwest Biotherapeutics, Inc. (NWBO)
USD 0.27
(1.89%)
USD 0.27
(1.89%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -53.63 Million | -52.77 Million | -38.29 Million | -32.09 Million | -31.85 Million | -34.58 Million |
| Net Income | -62.59 Million | -105.03 Million | 179.12 Million | -529.82 Million | -20.29 Million | -35.79 Million |
| Depreciation & Amortization | 1.73 Million | 1.5 Million | 586 Thousand | 425 Thousand | -301 Thousand | 1.29 Million |
| Deferred income taxes | -50 Thousand | - | -239.18 Million | 436.93 Million | -9.88 Million | -21.66 Million |
| Stock-based compensation | 4.4 Million | 12.29 Million | 15.49 Million | 52.2 Million | 1.82 Million | 14.28 Million |
| Change in working capital | -3.69 Million | 7.2 Million | 2.72 Million | -35 Thousand | -4.62 Million | 944 Thousand |
| Other non-cash items | 6.56 Million | 31.25 Million | 2.94 Million | 8.19 Million | 1.43 Million | 6.35 Million |
| Investing Cash Flow | -3.43 Million | -2.9 Million | -6.01 Million | -8.14 Million | -360 Thousand | 45.4 Million |
| Investments in PPE | -3.43 Million | -2.9 Million | -6.01 Million | -6.61 Million | -360 Thousand | -193 Thousand |
| Acquisitions | - | - | - | -1.53 Million | - | 45.59 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -3.43 Million | -2.9 Million | -6.01 Million | 1.00 | -360 Thousand | 45.59 Million |
| Financing Cash Flow | 52.75 Million | 41.96 Million | 48.13 Million | 52.69 Million | 9.95 Million | 7.87 Million |
| Debt repayment | -32.95 Million | -111 Thousand | -5.82 Million | -2.02 Million | -6.14 Million | -18.28 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 15.04 Million | 39.29 Million | 4.07 Million | 26.81 Million | 6.87 Million | 1.16 Million |
| Other Financing Activities | 19.8 Million | 41.85 Million | 49.89 Million | 27.9 Million | 9.22 Million | 24.99 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -4.42 Million | 6.84 Million | -597 Thousand | 2.13 Million | -3.71 Million | 3.56 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 731 Thousand | 363 Thousand | 3.32 Million | -2.16 Million | -911 Thousand | -2.62 Million |
| Cash at beginning of period | 6.96 Million | 15.16 Million | 9.98 Million | 372 Thousand | 22.22 Million | 117 Thousand |
| Cash at end of period | 2.12 Million | 6.96 Million | 15.16 Million | 9.98 Million | 372 Thousand | 22.22 Million |
| Capital Expenditure | -3.43 Million | -2.9 Million | -6.01 Million | -6.61 Million | -360 Thousand | -193 Thousand |
| Effect of forex changes on cash | -523 Thousand | 5.5 Million | 1.36 Million | -2.85 Million | 415 Thousand | 3.42 Million |
| Net cash flow / Change in cash | -4.83 Million | -8.2 Million | 5.18 Million | 9.61 Million | -21.85 Million | 22.1 Million |
| Free Cash Flow | -57.07 Million | -55.67 Million | -44.31 Million | -38.7 Million | -32.21 Million | -34.77 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -17.86 Million | -18.31 Million | -18.91 Million | -62.59 Million | -18.58 Million | -14.44 Million |
| Depreciation & Amortization | 516 Thousand | 505 Thousand | 421 Thousand | 1.73 Million | 489 Thousand | 421 Thousand |
| Deferred income taxes | - | - | -7.26 Million | -50 Thousand | 1.34 Million | 365 Thousand |
| Stock-based compensation | 1.15 Million | 1.16 Million | 1.57 Million | 4.4 Million | 1.62 Million | 278 Thousand |
| Change in working capital | 833 Thousand | 3.27 Million | -5.01 Million | -3.69 Million | 140 Thousand | 1.23 Million |
| Other non-cash items | 942 Thousand | -589 Thousand | 12.24 Million | 6.56 Million | 1.06 Million | 625 Thousand |
| Investing Cash Flow | -521 Thousand | -239 Thousand | -418 Thousand | -3.43 Million | -437 Thousand | -1.24 Million |
| Investments in PPE | -521 Thousand | -239 Thousand | -418 Thousand | -3.43 Million | -437 Thousand | -1.24 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | -239 Thousand | -3.43 Million | -3.43 Million | - | - |
| Financing Cash Flow | 17.13 Million | 12.08 Million | 14.41 Million | 52.75 Million | 17.12 Million | 8.63 Million |
| Debt repayment | -9.75 Million | -7.1 Million | -10.46 Million | -32.95 Million | -11.54 Million | -1.04 Million |
| Dividends payments | -441 Thousand | - | - | - | - | - |
| Common Stock Repurchased | - | - | 3.42 Million | - | - | - |
| Common Stock Issuance | 7.38 Million | 4.93 Million | 3.55 Million | 15.04 Million | 5.17 Million | 3.68 Million |
| Other Financing Activities | 3.07 Million | 50 Thousand | 3.95 Million | 19.8 Million | 5.57 Million | 7.59 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 413 Thousand | 3.72 Million | -4.84 Million | -4.42 Million | -1.38 Million | 1.16 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 420 Thousand | -442 Thousand | -175 Thousand | 731 Thousand | 1.52 Million | 70 Thousand |
| Cash at beginning of period | 2.47 Million | 2.12 Million | 6.09 Million | 6.96 Million | 1.42 Million | 6.19 Million |
| Cash at end of period | 2.88 Million | 2.47 Million | 2.12 Million | 2.12 Million | 6.09 Million | 1.42 Million |
| Capital Expenditure | -521 Thousand | -239 Thousand | -418 Thousand | -3.43 Million | -437 Thousand | -1.24 Million |
| Effect of forex changes on cash | -17 Thousand | 912 Thousand | -1.01 Million | -523 Thousand | 1.9 Million | -635 Thousand |
| Net cash flow / Change in cash | 403 Thousand | 352 Thousand | -3.97 Million | -4.83 Million | 4.67 Million | -4.76 Million |
| Free Cash Flow | -16.71 Million | -12.64 Million | -17.37 Million | -57.07 Million | -14.35 Million | -12.77 Million |
002942
MYCR
0HI3
1816
IMTX
GEKTERNA